Literature DB >> 6119719

Does a plasma level of chlorpromazine help?

T Van Putten, P R May, D J Jenden.   

Abstract

Forty-eight newly admitted schizophrenic patients were treated with a fixed, conservative (6.6 mg/kg) dose of chlorpromazine (CPZ) for 28 days. CPZ plasma levels were measured by a gas chromatography mass spectrometry method (GCMS) using 2H6-chlorpromazine as an internal standard. At the end of the fixed-dose period, "responders" had the same plasma levels as "non-responders", suggesting that lack of response is primarily a matter of the illness' sensitivity to CPZ, not to a plasma level below some therapeutic window. After the fixed-dose period, the dosage of CPZ was increased in the "non-responders" by physician's choice. Improvement occurred over a wide range of 10-225 picomoles (3-72 ng)/ml. Above 300 picomoles (95 ng/ml) 4 inaccessible patients eventually became much worse, suggesting psychotoxicity. It is in the inaccessible patient whose illness is only minimally, or not at all, sensitive to CPZ that a plasma level might be especially useful. Interpretation of plasma levels is complicated by the speed of response: some initial non-responders improved by the 56th day of treatment on very conservative plasma levels.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6119719     DOI: 10.1017/s0033291700041222

Source DB:  PubMed          Journal:  Psychol Med        ISSN: 0033-2917            Impact factor:   7.723


  3 in total

Review 1.  Plasma level monitoring of antipsychotic drugs. Clinical utility.

Authors:  S G Dahl
Journal:  Clin Pharmacokinet       Date:  1986 Jan-Feb       Impact factor: 6.447

2.  Interaction of chlorpromazine and nortriptyline in patients with schizophrenia.

Authors:  S Loga; S Curry; M Lader
Journal:  Clin Pharmacokinet       Date:  1981 Nov-Dec       Impact factor: 6.447

3.  Plasma levels of thiothixene by radioreceptor assay: clinical usefulness.

Authors:  T Van Putten; P R May; S R Marder; J N Wilkins; B J Rosenberg
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.